PIK3CA

Overview

PIK3CA encodes the catalytic p110α subunit of class I phosphoinositide 3-kinase (PIK3CA), a central signaling enzyme in pathways that regulate cell growth, survival, metabolism, and proliferation. As a protein target, PIK3CA is especially important in oncology because activating mutations can drive aberrant PI3K/AKT signaling and contribute to tumor progression and therapy resistance.

In biomedical research, PIK3CA is frequently studied as a drug target for selective PIK3CA inhibition. This is particularly relevant in Cancers such as cervical cancer and breast cancer, where mutant PIK3CA can create a dependency on PIK3CA signaling. Recent studies also place PIK3CA within broader pathway networks involving EGFR/SRC-mediated EMT, KRAS, mitogen-activated protein kinase 1 (MAPK1), PTGS2, and the PI3K/Akt signaling pathway, underscoring its role as a hub in oncogenic signaling.

Recent Publications Summary

Recent studies have established PIK3CA mutations as clinically actionable driver events in multiple cancer types, with PI3K inhibitors demonstrating selective anti-tumor efficacy in PIK3CA-mutant tumors. In cervical cancer, the PI3K-α-specific inhibitors Alpelisib and Inavolisib selectively suppressed proliferation in PIK3CA-mutant cell lines with minimal effects in wild-type cells, with Alpelisib further reducing HPV16 E7, PD-L1, YAP1, and EGFR expression specifically in PIK3CA-mutant models and enhancing responses to HPV-directed T cell therapy 41980433Apr. The selective PI3K-α inhibitor CYH33 significantly attenuated metastasis in lung squamous cell carcinoma xenografts by suppressing tumor cell motility and reducing cancer-associated fibroblast infiltration 41545755Jan, and PI3K inhibition with taselisib was evaluated in combination with tamoxifen for metastatic hormone receptor-positive/HER2-negative breast cancer 41632450Feb. PIK3CA mutations also emerged as biomarkers of therapeutic interest in estrogen receptor-positive breast cancer 42310300Jun and metastatic urothelial carcinoma 42413983Jul.

Mechanistic investigations revealed complex signaling networks in PIK3CA-mutant cells that influenced therapeutic responses and resistance mechanisms. Proteomic and phosphoproteomic profiling of E545K and H1047R PIK3CA mutants in breast epithelial cells uncovered distinct mutation-specific signaling programs: both showed basal MAPK activation yet displayed divergent MAPK phosphorylation dynamics upon PI3K-α inhibition; bypass signaling through MAPK and insulin-dependent pathways partially counteracted PI3K inhibitor-induced suppression 42204977May. In urothelial carcinoma, oncogenic PIK3CA mutations enhanced tumor immunogenicity through the IRF1-NLRC5-MHC-I axis, promoting enhanced antigen presentation and CD8+ T cell proliferation, with effects further amplified by anti-PD-L1 co-treatment 42413983Jul. In non-small cell lung cancer, PIK3CA functioned as a transcriptional target in the TRERNA1-KAT6A-mediated ferroptosis suppression pathway, where TRIM24 activated PIK3CA transcription to inhibit ferroptosis and enhance cell survival 42340519Jun.

PIK3CA emerged as a validated molecular target for diverse small molecules and natural compounds identified through network pharmacology and molecular docking approaches. Pterostilbene, a dietary polyphenol, ameliorated cyclophosphamide-induced liver injury, with network pharmacology revealing PIK3CA among key molecular targets enriched in inflammatory and oxidative stress pathways 42444162Jul. Psoralen exhibited strong binding affinity to PIK3CA in molecular docking and dynamics simulations and suppressed renal cell carcinoma proliferation through PI3K/AKT pathway inhibition 41929235Apr, while bioactive compounds from Clerodendrum species showed favorable docking interactions with both PIK3CA and AKT1 42235855Jun. Sanguinarine and its Phase I and Phase II metabolites engaged a protein network centered on PIK3CA and SRC, enriched in pathways in cancer and chemical carcinogenesis 41844053Mar, and di-(2-ethylhexyl) terephthalate (DOTP) promoted breast cancer progression through multiple targets including PIK3CA 41780785Mar.

Detection and characterization of PIK3CA alterations provided diagnostic and prognostic insights across disease contexts. A CRISPR-Cas12a-based liquid biopsy assay detected PIK3CA point mutations in circulating cell-free DNA from clinical plasma samples with 90.48% sensitivity and 100% specificity, enabling mutation profiling for precision oncology 42172311May. PIK3CA amplifications were documented as molecular co-alterations in esophageal adenocarcinoma 42527418Jul, and PIK3CA mutations were identified in colon cancer arising in patients with multiple primary malignancies 42478852Jul. Additionally, somatic mosaic PIK3CA variants were implicated in PIK3CA-related overgrowth spectrum (PROS) and CLOVES syndrome, where specific PIK3CA gain-of-function mutations (p.Glu545Ala) drove segmental overgrowth and complex vascular malformations 42334730Jun.

What Changes, What Holds

1. PIK3CA mutations now read as actionable predictors of PI3K-α inhibitor benefit across several Cancers
REINFORCES These studies strengthen the baseline view of PIK3CA as a therapeutically important oncogenic target by showing that mutant tumors can be selectively suppressed by PI3K inhibition, with some settings also gaining combination-therapy value. The main change is practical rather than conceptual: PIK3CA status looks more useful for treatment selection and response enrichment than the overview already implied, especially in cervical, breast, lung squamous, and urothelial Cancers 41980433Apr41545755Jan.

2. PIK3CA-mutant tumors can rewire signaling and immunity in ways that shape resistance and response
NEW DIRECTION The new work adds roles not covered in the overview: mutation-specific MAPK bypass, insulin-linked escape from PI3K blockade, enhanced antigen presentation, and transcriptional control of ferroptosis suppression. These findings do not displace the established PI3K/AKT oncogenic role, but they show that PIK3CA-mutant biology is more networked and context dependent than a simple growth-signaling node. The mechanistic evidence is still early and largely preclinical, so the exact generality remains unsettled 42204977May42413983Jul.

3. PIK3CA is becoming a recurring docking and network-pharmacology target for noncanonical small molecules
REINFORCES This work does not change what PIK3CA is understood to do; it extends the list of compounds reported to engage it and supports the idea that the protein remains a frequent node in screening and docking pipelines. The added studies are hypothesis-generating rather than practice-changing, and they mainly reinforce the baseline’s view of PIK3CA as a drug target rather than establishing a new biological role 41929235Apr42235855Jun.

4. PIK3CA alterations are now being used more directly for liquid biopsy and disease stratification
NEW DIRECTION The liquid-biopsy assay and the disease-association reports move PIK3CA beyond target biology into detection and classification, which the overview does not cover. That makes this a methodological and translational expansion rather than a contradiction of the baseline. The overgrowth-spectrum findings also broaden the entity’s relevance outside oncology, but they fit as an added clinical context, not a replacement for its established cancer signaling role 42172311May42334730Jun.

Overview update candidates: mutant PIK3CA as a predictive biomarker for PI3K inhibitor sensitivity and combination-therapy selection; mutation-specific bypass signaling; immune modulation; and ferroptosis-related regulation; cfDNA mutation detection for precision oncology; PIK3CA as a marker in overgrowth syndromes and selected tumor co-alteration contexts.